Last reviewed · How we verify
ATM Kinase Inhibitor AZD1390
ATM Kinase Inhibitor AZD1390 is a ATM kinase inhibitor Small molecule drug developed by Children's Oncology Group. It is currently in Phase 1 development for Glioblastoma. Also known as: AZD-1390, AZD1390.
ATM kinase inhibitor
AZD1390 is a kinase inhibitor being studied in a Phase I clinical trial for the treatment of metastatic solid tumor cancer. The trial is assessing the safety and tolerability of AZD1390 in combination with stereotactic body radiotherapy.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ATM Kinase Inhibitor AZD1390 |
|---|---|
| Also known as | AZD-1390, AZD1390 |
| Sponsor | Children's Oncology Group |
| Drug class | ATM kinase inhibitor |
| Target | ATM |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZD1390 is a potent and selective inhibitor of ataxia-telangiectasia mutated (ATM) kinase, which plays a critical role in the DNA damage response pathway.
Approved indications
- Glioblastoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma (PHASE1)
- AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients (EARLY_PHASE1)
- Sarcomas and DDR-Inhibition; a Combined Modality Study (PHASE1)
- A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer (PHASE1)
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (PHASE1)
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (PHASE2, PHASE3)
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer (PHASE1)
- AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATM Kinase Inhibitor AZD1390 CI brief — competitive landscape report
- ATM Kinase Inhibitor AZD1390 updates RSS · CI watch RSS
- Children's Oncology Group portfolio CI
Frequently asked questions about ATM Kinase Inhibitor AZD1390
What is ATM Kinase Inhibitor AZD1390?
How does ATM Kinase Inhibitor AZD1390 work?
What is ATM Kinase Inhibitor AZD1390 used for?
Who makes ATM Kinase Inhibitor AZD1390?
Is ATM Kinase Inhibitor AZD1390 also known as anything else?
What drug class is ATM Kinase Inhibitor AZD1390 in?
What development phase is ATM Kinase Inhibitor AZD1390 in?
What are the side effects of ATM Kinase Inhibitor AZD1390?
What does ATM Kinase Inhibitor AZD1390 target?
Related
- Drug class: All ATM kinase inhibitor drugs
- Target: All drugs targeting ATM
- Manufacturer: Children's Oncology Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Glioblastoma
- Also known as: AZD-1390, AZD1390
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing